Buckley LA - Search Results

1

Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.

Buckley LA, Benson K, Davis-Bruno K, Dempster M, Finch GL, Harlow P, Haggerty HG, Hart T, Kinter L, Leighton JK, McNulty J, Roskos L, Saber H, Stauber A, Tabrizi M. Buckley LA, et al. Int J Toxicol. 2008 Jul-Aug;27(4):303-12. doi: 10.1080/10915810802367016. Int J Toxicol. 2008. PMID: 18821393

2

Biologically-based models of dioxin pharmacokinetics.

Buckley LA. Buckley LA. Toxicology. 1995 Sep 1;102(1-2):125-31. doi: 10.1016/0300-483x(95)03041-d. Toxicology. 1995. PMID: 7482547 Review.

3

High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.

Buckley LA, Dorato MA. Buckley LA, et al. Regul Toxicol Pharmacol. 2009 Aug;54(3):301-7. doi: 10.1016/j.yrtph.2009.05.015. Epub 2009 May 27. Regul Toxicol Pharmacol. 2009. PMID: 19477212

4

Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.

Buckley LA, Chapman K, Burns-Naas LA, Todd MD, Martin PL, Lansita JA. Buckley LA, et al. Int J Toxicol. 2011 Oct;30(5):583-90. doi: 10.1177/1091581811415875. Int J Toxicol. 2011. PMID: 22013138 Review.

5

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

Buckley LA, Sanbuissho A, Starling JJ, Knadler MP, Iversen PW, Jakubowski JA. Buckley LA, et al. Int J Toxicol. 2012 Jul-Aug;31(4):317-25. doi: 10.1177/1091581812445073. Epub 2012 Jun 12. Int J Toxicol. 2012. PMID: 22692976

6

Toxicology testing in drug discovery and development.

Dorato MA, Buckley LA. Dorato MA, et al. Among authors: buckley la. Curr Protoc Toxicol. 2007 Feb;Chapter 19:Unit19.1. doi: 10.1002/0471141755.tx1901s31. Curr Protoc Toxicol. 2007. PMID: 23045141

7

Drug Development 101: A Primer.

Buckley LA, Bebenek I, Cornwell PD, Hodowanec A, Jensen EC, Murphy C, Ghantous HN. Buckley LA, et al. Int J Toxicol. 2020 Sep/Oct;39(5):379-396. doi: 10.1177/1091581820939083. Epub 2020 Aug 7. Int J Toxicol. 2020. PMID: 32762387

8

Pharmaceutical Industry Perspective on the Non-Clinical Evaluation of Novel Excipients: Results From an Industry Survey Conducted by the IQ Novel Excipient Working Group.

Giffen PS, Buckley LA, Pinkstaff J. Giffen PS, et al. Among authors: buckley la. Int J Toxicol. 2023 Dec;42(6):480-488. doi: 10.1177/10915818231189703. Epub 2023 Jul 14. Int J Toxicol. 2023. PMID: 37450849

9

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates.

Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V. Chapman K, et al. MAbs. 2009 Sep-Oct;1(5):505-16. doi: 10.4161/mabs.1.5.9676. Epub 2009 Sep 30. MAbs. 2009. PMID: 20065651 Free PMC article.

10

Toxicology in the drug discovery and development process.

Dorato MA, Buckley LA. Dorato MA, et al. Among authors: buckley la. Curr Protoc Pharmacol. 2006 Apr;Chapter 10:Unit10.3. doi: 10.1002/0471141755.ph1003s32. Curr Protoc Pharmacol. 2006. PMID: 22294168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters